This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cenci, E Articles by Bistoni, F Search for Related Content PubMed PubMed Citation Articles by Cenci, E Articles by Bistoni, F

 Previous Article  |  Next Article 

Infect Immun. 1991 March; 59(3): 868-872

Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration.

Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.

ABSTRACT

Serum and tissue concentrations of the macrophage-specific colony-stimulating factor (CSF-1) and the number of CSF-1-responsive cells in bone marrow were investigated in mice chronically infected with a low-virulence strain of the opportunistic zoopathogenic yeast Candida albicans. CSF-1 levels in serum, brain, kidney, liver, and lung were significantly increased shortly after infection and remained elevated during the 2 weeks preceding the onset of specific T cell-dependent immunity. The number of monocytic precursor cells was also increased in the bone marrow of infected mice. When macrophages from naive donors were exposed in vitro to purified murine CSF-1, their anticandidal activity in vitro appeared to be enhanced. CSF-1 was also administered in vivo to prospective recipients of a lethal C. albicans challenge. The results showed that the factor could effectively potentiate the animals' resistance to the yeast, as shown by increased survival times and reduced recovery of viable C. albicans from the organs of the CSF-1-treated mice. Therefore, the present data suggest that CSF-1 is likely to contribute to early resistance to fungal infection and could be successfully exploited in experimental models of antifungal immunotherapy.

This article has been cited by other articles:

• Sweet, M. J., Campbell, C. C., Sester, D. P., Xu, D., McDonald, R. C., Stacey, K. J., Hume, D. A., Liew, F. Y. (2002). Colony-Stimulating Factor-1 Suppresses Responses to CpG DNA and Expression of Toll-Like Receptor 9 but Enhances Responses to Lipopolysaccharide in Murine Macrophages. J. Immunol. 168: 392-399 [Abstract] [Full Text]  
• Han, Y., Kozel, T. R., Zhang, M. X., MacGill, R. S., Carroll, M. C., Cutler, J. E. (2001). Complement Is Essential for Protection by an IgM and an IgG3 Monoclonal Antibody Against Experimental, Hematogenously Disseminated Candidiasis. J. Immunol. 167: 1550-1557 [Abstract] [Full Text]  
• Kuhara, T., Uchida, K., Yamaguchi, H. (2000). Therapeutic Efficacy of Human Macrophage Colony-Stimulating Factor, Used Alone and in Combination with Antifungal Agents, in Mice with Systemic Candida albicans Infection. Antimicrob. Agents Chemother. 44: 19-23 [Abstract] [Full Text]  
• Sester, D. P., Beasley, S. J., Sweet, M. J., Fowles, L. F., Cronau, S. L., Stacey, K. J., Hume, D. A. (1999). Bacterial/CpG DNA Down-Modulates Colony Stimulating Factor-1 Receptor Surface Expression on Murine Bone Marrow-Derived Macrophages with Concomitant Growth Arrest and Factor-Independent Survival. J. Immunol. 163: 6541-6550 [Abstract] [Full Text]